Josefin Ansund1,2, Sara Mijwel3, Kate A Bolam3, Renske Altena4,5, Yvonne Wengström3,4, Eric Rullman1,2, Helene Rundqvist6,7. 1. Department of Laboratory Medicine, Karolinska Institutet, Stockholm, Sweden. 2. Unit of Clinical Physiology, Karolinska University Hospital, Stockholm, Sweden. 3. Department of Neurobiology, Care Sciences and Society, Karolinska Institutet, Stockholm, Sweden. 4. Cancer Theme, Karolinska University Hospital, Stockholm, Sweden. 5. Department of Oncology and Pathology, Karolinska Institutet, Stockholm, Sweden. 6. Department of Laboratory Medicine, Karolinska Institutet, Stockholm, Sweden. Helene.Rundqvist@ki.se. 7. Unit of Clinical Physiology, Karolinska University Hospital, Stockholm, Sweden. Helene.Rundqvist@ki.se.
Abstract
BACKGROUND: Adjuvant systemic breast cancer treatment improves disease specific outcomes, but also presents with cardiac toxicity. In this post-hoc exploratory analysis of the OptiTrain trial, the effects of exercise on cardiotoxicity were monitored by assessing fitness and biomarkers over the intervention and into survivorship. Methods; Women starting chemotherapy were randomized to 16-weeks of resistance and high-intensity interval training (RT-HIIT), moderate-intensity aerobic and high-intensity interval training (AT-HIIT), or usual care (UC). Outcome measures included plasma troponin-T (cTnT), Nt-pro-BNP and peak oxygen uptake (VO2peak), assessed at baseline, post-intervention, and at 1- and 2-years. RESULTS: For this per-protocol analysis, 88 women met criteria for inclusion. Plasma cTnT increased in all groups post-intervention. At the 1-year follow-up, Nt-pro-BNP was lower in the exercise groups compared to UC. At 2-years there was a drop in VO2peak for patients with high cTnT and Nt-pro-BNP. Fewer patients in the RT-HIIT group fulfilled biomarker risk criteria compared to UC (OR 0.200; 95% CI = 0.055-0.734). CONCLUSIONS: In this cohort, high-intensity exercise was associated with lower levels of NT-proBNP 1-year post-baseline, but not with cTnT directly after treatment completion. This may, together with the preserved VO2peak in patients with low levels of biomarkers, indicate a long-term cardioprotective effect of exercise. TRIAL REGISTRATION: Clinicaltrials. govNCT02522260 , Registered 13th of august 2015 - Retrospectively Registered.
RCT Entities:
BACKGROUND: Adjuvant systemic breast cancer treatment improves disease specific outcomes, but also presents with cardiac toxicity. In this post-hoc exploratory analysis of the OptiTrain trial, the effects of exercise on cardiotoxicity were monitored by assessing fitness and biomarkers over the intervention and into survivorship. Methods; Women starting chemotherapy were randomized to 16-weeks of resistance and high-intensity interval training (RT-HIIT), moderate-intensity aerobic and high-intensity interval training (AT-HIIT), or usual care (UC). Outcome measures included plasma troponin-T (cTnT), Nt-pro-BNP and peak oxygen uptake (VO2peak), assessed at baseline, post-intervention, and at 1- and 2-years. RESULTS: For this per-protocol analysis, 88 women met criteria for inclusion. Plasma cTnT increased in all groups post-intervention. At the 1-year follow-up, Nt-pro-BNP was lower in the exercise groups compared to UC. At 2-years there was a drop in VO2peak for patients with high cTnT and Nt-pro-BNP. Fewer patients in the RT-HIIT group fulfilled biomarker risk criteria compared to UC (OR 0.200; 95% CI = 0.055-0.734). CONCLUSIONS: In this cohort, high-intensity exercise was associated with lower levels of NT-proBNP 1-year post-baseline, but not with cTnT directly after treatment completion. This may, together with the preserved VO2peak in patients with low levels of biomarkers, indicate a long-term cardioprotective effect of exercise. TRIAL REGISTRATION: Clinicaltrials. govNCT02522260 , Registered 13th of august 2015 - Retrospectively Registered.
Authors: Kathryn H Schmitz; Kerry S Courneya; Charles Matthews; Wendy Demark-Wahnefried; Daniel A Galvão; Bernardine M Pinto; Melinda L Irwin; Kathleen Y Wolin; Roanne J Segal; Alejandro Lucia; Carole M Schneider; Vivian E von Gruenigen; Anna L Schwartz Journal: Med Sci Sports Exerc Date: 2010-07 Impact factor: 5.411
Authors: Patrick T Bradshaw; June Stevens; Nikhil Khankari; Susan L Teitelbaum; Alfred I Neugut; Marilie D Gammon Journal: Epidemiology Date: 2016-01 Impact factor: 4.822
Authors: Y Wengström; K A Bolam; S Mijwel; C J Sundberg; M Backman; M Browall; J Norrbom; H Rundqvist Journal: BMC Cancer Date: 2017-02-06 Impact factor: 4.430
Authors: Sara Mijwel; Malin Backman; Kate A Bolam; Emil Olofsson; Jessica Norrbom; Jonas Bergh; Carl Johan Sundberg; Yvonne Wengström; Helene Rundqvist Journal: Breast Cancer Res Treat Date: 2018-01-18 Impact factor: 4.872
Authors: Dongqing Chen; Conagh Kelly; Tatt Jhong Haw; Janine M Lombard; Ina I C Nordman; Amanda J Croft; Doan T M Ngo; Aaron L Sverdlov Journal: Curr Heart Fail Rep Date: 2021-11-03
Authors: Willeke R Naaktgeboren; Wim G Groen; Judy N Jacobse; Lars C Steggink; Annemiek M E Walenkamp; Wim H van Harten; Martijn M Stuiver; Neil K Aaronson; Berthe M P Aleman; Peter van der Meer; Michael Schaapveld; Gabe S Sonke; Jourik A Gietema; Flora E van Leeuwen; Anne M May Journal: JACC CardioOncol Date: 2022-04-19
Authors: Dong-Woo Kang; Rebekah L Wilson; Cami N Christopher; Amber J Normann; Oscar Barnes; Jordan D Lesansee; Gyuhwan Choi; Christina M Dieli-Conwright Journal: Front Cardiovasc Med Date: 2022-01-14
Authors: Stephanie J Kendall; Jodi E Langley; Mohsen Aghdam; Bruce N Crooks; Nicholas Giacomantonio; Stefan Heinze-Milne; Will J Johnston; Melanie R Keats; Sharon L Mulvagh; Scott A Grandy Journal: Curr Oncol Date: 2022-09-03 Impact factor: 3.109
Authors: Marco Invernizzi; Lorenzo Lippi; Arianna Folli; Alessio Turco; Lorenzo Zattoni; Antonio Maconi; Alessandro de Sire; Nicola Fusco Journal: Front Mol Biosci Date: 2022-09-08